Table 6.
Frequency of grade 3–4 adverse events in the FEC and PE arms
| Adverse event | FEC arm [cases (%)] | PE arm [cases (%)] | P value |
|---|---|---|---|
| Hematologic | |||
| Neutropenia | 9 (5.96) | 17 (11.97) | 0.031 |
| Anemia | 6 (4.00) | 10 (7.04) | 0.248 |
| Thrombocytopenia | 5 (3.31) | 7 (4.93) | 0.485 |
| Non-hematologic | |||
| Nausea | 4 (2.64) | 4 (2.82) | 0.458 |
| Vomiting | 2 (1.32) | 3 (2.11) | 0.603 |
| Diarrhea | 2 (1.32) | 4 (2.82) | 0.951 |
| Constipation | 3 (1.99) | 4 (2.82) | 0.267 |
| Hair loss | 24 (15.79) | 28 (19.72) | 0.583 |
| Dermatitis | 8 (5.30) | 11 (7.75) | 0.395 |
| Febrile | 1 (0.66) | 1 (0.70) | 0.965 |
| Fatigue | 7 (4.64) | 10 (7.04) | 0.379 |
| Hand-foot syndrome | 6 (3.97) | 5 (3.52) | 0.913 |
| Allergy | 0 (0.00) | 1 (0.70) | 0.143 |
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen